Invasive breast carcinoma
Information
- Disease name
- Invasive breast carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02530489 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | February 4, 2016 | December 31, 2025 |
| NCT01750073 | Active, not recruiting | Phase 2 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | December 7, 2012 | June 2026 |
| NCT02779855 | Active, not recruiting | Phase 1/Phase 2 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | May 2, 2017 | August 31, 2024 |
| NCT03554044 | Active, not recruiting | Phase 1 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | February 5, 2020 | April 30, 2025 |
| NCT02860000 | Active, not recruiting | Phase 2 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | July 6, 2017 | December 31, 2026 |
| NCT02876107 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | October 6, 2016 | October 31, 2025 |
| NCT03414970 | Active, not recruiting | Phase 3 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | March 12, 2018 | August 2035 |
| NCT02883062 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | August 2, 2017 | January 23, 2025 |
| NCT03359954 | Active, not recruiting | Phase 2 | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer | November 16, 2017 | October 31, 2025 |
| NCT03345420 | Active, not recruiting | Phase 2 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer | December 12, 2017 | September 3, 2025 |
| NCT03077841 | Active, not recruiting | Phase 2/Phase 3 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer | March 6, 2017 | August 31, 2024 |
| NCT02954874 | Active, not recruiting | Phase 3 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | January 18, 2017 | May 31, 2026 |
| NCT02957968 | Active, not recruiting | Phase 2 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | January 24, 2017 | February 28, 2025 |
| NCT00877500 | Active, not recruiting | Phase 2 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | March 30, 2009 | December 31, 2024 |
| NCT01245712 | Active, not recruiting | Phase 2 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | November 15, 2010 | December 31, 2032 |
| NCT01266642 | Active, not recruiting | Phase 2 | Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer | February 8, 2011 | November 30, 2025 |
| NCT01272037 | Active, not recruiting | Phase 3 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | January 15, 2011 | October 1, 2032 |
| NCT04481113 | Active, not recruiting | Phase 1 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | June 7, 2021 | December 30, 2025 |
| NCT04001829 | Active, not recruiting | Phase 2 | Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | August 9, 2019 | March 31, 2027 |
| NCT01334021 | Active, not recruiting | Phase 2 | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer | May 31, 2011 | December 31, 2024 |
| NCT05012176 | Active, not recruiting | N/A | An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors | November 1, 2021 | December 31, 2024 |
| NCT02445391 | Active, not recruiting | Phase 3 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | October 20, 2015 | March 29, 2031 |
| NCT02453620 | Active, not recruiting | Phase 1 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | February 12, 2016 | August 30, 2024 |
| NCT00601900 | Active, not recruiting | Phase 3 | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer | May 15, 2008 | July 10, 2024 |
| NCT02515110 | Active, not recruiting | N/A | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer | August 4, 2015 | January 24, 2025 |
| NCT04897009 | Active, not recruiting | Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer | June 9, 2021 | May 15, 2025 | |
| NCT01622868 | Completed | Phase 2 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | December 6, 2012 | May 20, 2022 |
| NCT00429182 | Completed | Phase 2 | Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | June 2007 | February 2012 |
| NCT01344031 | Completed | Phase 1 | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer | April 21, 2011 | |
| NCT01434303 | Completed | Phase 1 | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | January 10, 2012 | February 16, 2016 |
| NCT01753908 | Completed | Early Phase 1 | Broccoli Sprout Extract in Treating Patients With Breast Cancer | May 21, 2013 | August 23, 2018 |
| NCT01846091 | Completed | Phase 1 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | April 9, 2013 | November 26, 2019 |
| NCT01849250 | Completed | Phase 2 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | May 2013 | April 22, 2020 |
| NCT01964924 | Completed | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | October 2, 2013 | April 23, 2018 |
| NCT02282345 | Completed | Phase 2 | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | April 16, 2015 | June 7, 2022 |
| NCT02370277 | Completed | Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer | December 16, 2014 | August 22, 2018 | |
| NCT02456857 | Completed | Phase 2 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | January 12, 2016 | May 24, 2023 |
| NCT02526498 | Completed | Phase 2 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery | July 15, 2015 | March 31, 2021 |
| NCT02689427 | Completed | Phase 2 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | September 22, 2016 | November 15, 2023 |
| NCT03323658 | Completed | Phase 1 | Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | June 15, 2018 | March 25, 2022 |
| NCT03454529 | Completed | Phase 2 | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | March 9, 2018 | October 6, 2021 |
| NCT03518242 | Completed | Phase 1 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer | June 6, 2018 | May 4, 2022 |
| NCT03679559 | Completed | N/A | Exercise in Improving Health and Quality of Life in Breast Cancer Survivors | October 6, 2017 | June 2, 2022 |
| NCT03789877 | Completed | N/A | A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity | January 16, 2019 | February 5, 2021 |
| NCT04022772 | Completed | N/A | Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer | July 31, 2019 | July 27, 2023 |
| NCT04087057 | Completed | Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer | August 23, 2019 | April 16, 2024 | |
| NCT04294225 | Completed | Phase 2 | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer | April 28, 2020 | December 12, 2022 |
| NCT04667481 | Completed | N/A | Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial | January 5, 2022 | November 10, 2022 |
| NCT05036083 | Completed | N/A | Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion | March 19, 2021 | March 25, 2024 |
| NCT05071677 | Completed | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer | May 3, 2021 | August 7, 2023 | |
| NCT03606967 | Recruiting | Phase 2 | Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | April 13, 2021 | December 31, 2024 |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT04871516 | Recruiting | N/A | Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer | May 18, 2021 | January 31, 2024 |
| NCT04959474 | Recruiting | Phase 2 | SABR-CaRe in Early Stage Breast Cancer | August 23, 2021 | January 1, 2026 |
| NCT00477100 | Recruiting | Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | April 17, 2007 | April 30, 2030 | |
| NCT05023967 | Recruiting | Phase 2 | Metformin and Nightly Fasting in Women With Early Breast Cancer | April 4, 2023 | November 20, 2025 |
| NCT05710328 | Recruiting | Phase 2 | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial | May 10, 2023 | March 31, 2025 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05786664 | Recruiting | Breast Cancer Survivorship Biorepository | April 11, 2022 | April 11, 2028 | |
| NCT02945579 | Recruiting | N/A | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | January 20, 2017 | January 31, 2026 |
| NCT02918474 | Recruiting | N/A | Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer | April 28, 2017 | September 30, 2026 |
| NCT02912312 | Recruiting | Phase 2 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | February 23, 2017 | February 28, 2031 |
| NCT05319873 | Recruiting | Phase 1/Phase 2 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | April 7, 2022 | April 1, 2026 |
| NCT05340673 | Recruiting | Phase 1 | Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer | June 21, 2022 | December 21, 2025 |
| NCT03796273 | Recruiting | Early Phase 1 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | March 13, 2019 | September 2024 |
| NCT03971409 | Recruiting | Phase 2 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | July 8, 2019 | June 30, 2025 |
| NCT03979508 | Recruiting | Phase 2 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | January 10, 2020 | July 31, 2024 |
| NCT02276443 | Recruiting | N/A | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | November 9, 2015 | November 30, 2026 |
| NCT04009044 | Recruiting | Phase 2 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | February 17, 2020 | June 25, 2024 |
| NCT05406232 | Recruiting | Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer | September 15, 2023 | December 31, 2026 | |
| NCT05447910 | Recruiting | Phase 2 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer | July 21, 2022 | June 15, 2025 |
| NCT04169542 | Recruiting | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | May 21, 2019 | March 31, 2026 | |
| NCT04266249 | Recruiting | Phase 2 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | March 13, 2020 | December 31, 2038 |
| NCT05464810 | Recruiting | Early Phase 1 | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | September 2, 2022 | April 15, 2025 |
| NCT04379570 | Recruiting | Phase 3 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | February 15, 2021 | October 2025 |
| NCT04457596 | Recruiting | Phase 3 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | January 6, 2021 | May 2035 |
| NCT04521764 | Recruiting | Phase 1 | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer | September 23, 2020 | August 15, 2027 |
| NCT04647916 | Recruiting | Phase 2 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | June 8, 2021 | December 2026 |
| NCT05545150 | Recruiting | Phase 2 | Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study | November 28, 2022 | July 1, 2024 |
| NCT03737695 | Suspended | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer | September 16, 2019 | November 15, 2024 | |
| NCT03188393 | Suspended | Phase 2 | Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery | April 13, 2017 | November 30, 2024 |
| NCT02037529 | Suspended | Phase 3 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer | January 17, 2014 | December 31, 2023 |
| NCT05327608 | Suspended | N/A | Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery | July 28, 2022 | May 1, 2024 |
| NCT00148720 | Terminated | Phase 2 | Capecitabine in Women With Operable Breast Cancer | September 2004 | |
| NCT03128619 | Terminated | Phase 1 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | August 2, 2017 | March 31, 2022 |
| NCT02876640 | Terminated | Phase 1 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | March 16, 2018 | June 3, 2022 |
| NCT04139993 | Terminated | Phase 1 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | August 31, 2020 | January 11, 2023 |
| NCT02856503 | Withdrawn | Phase 1/Phase 2 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | January 2019 | January 2024 |
| NCT05177796 | Withdrawn | Phase 2 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | March 11, 2022 | July 26, 2023 |
| NCT03238703 | Withdrawn | Phase 4 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | September 1, 2018 | March 14, 2025 |